Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2004

Study Completion Date

September 30, 2007

Conditions
Osteoarthritis, Knee
Interventions
DEVICE

Hylastan

Trial Locations (24)

21702

Arthritis & Osteoporosis Center of Maryland, Frederick

28844

Orthopaedische Gemeinschaftspraxis, Weyhe-Kirchweyhe

29526

Coastal Orthopedic Associates, Conway

33700

Clinique du Sport, Mérignac

33756

Orthopaedic Specialties of Tampa Bay, Clearwater

35209

Capstone Clinical Trials, Inc, Birmingham

37044

CHU Hôpital Trousseau Service de Rhumatologie, Tours

40509

Bluegrass Orthopaedics/Bluegrass Musculoskeletal Research, Lexington

60611

Northwestern Center for Clinical Research, Chicago

60612

Midwest Orthopedics at Rush University Medical Center, Chicago

61103

Rockford Health Physicians, Rockford

69121

St-Elisabeth Klinik, Orthopädisch Gemeinschaftspraxis, Heidelberg

69495

Centre Hospitalier Lyon-Sud, Service de Rhumatologie, Pierre-Bénite

71101

Orthopedic Specialists of Louisiana, Shreveport

78217

Unlimited Research, San Antonio

85050

Hope Research Institute, LLC, Phoenix

85712

Tucson Orthopedic Institute, PC, Tucson

97527

Orthopedic Center for Joint Replacement and Sports, Grants Pass

98166

Arthritis Northwest, Seattle

01610

Clinical Pharmacology Study Group, Worcester

L9C 7N4

Sir William Osler Health Institute, Hamilton

SO16 6YD

Southampton General Hospital, MRC Environmental Epidemiology Unit, Southampton

ME16 9QQ

Maidstone General Hospital & Tunbridge Wells NHS Trust, Maidstone

E11 1NR

Whipps Cross University Hospital NHS Trust, Arthritis Assessment, Physiotherapy Department, Leytonstone

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00139295 - Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter